KALY - Kali-Extracts Announces Reaching $1 Million In Sales

Date : 12/23/2019 @ 5:19PM
Source :InvestorsHub NewsWire
Stock : Kali Inc (PK) (KALY)
Quote : 0.0017  0.0 (0.00%) @ 12:05PM
Kali (PK) share price Chart

KALY - Kali-Extracts Announces Reaching $1 Million In Sales

Dallas, TX -- December 23, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced that the company has reached $1 million in sales.  Subject to an accounting review of its overall 2019 financials, management anticipates reporting over $1 million in revenue for 2019.  The major revenue contribution comes from KALY’s first hemp extraction contracts.    

KALY’s revenues through the end of Q3 come primarily from the sale of CBD infused products that have utilized KALY’s U.S. Patented Cannabis Extraction Process.  KALY produces its own line of CBD infused candies under the Hemp4mula brand name.  Hemp4mula includes both CBD Gum and CBD Gummies.  Both are available at www.USMJ.com.  KALY has also licensed its Patented Cannabis Extraction Process for the production of CBD and cannabis infused beverages. 

KALY has reported $173,300 for the three-month period ending September 30, 2019.  KALY’s year to date revenue through the period ending September 30, 2019 exceeds $300,000.  The company’s operation is profitable.

After executing its first CBD extraction contracts with hemp farming operations and commencing its first harvesting and extraction efforts, management now indicates a substantial addition to sales in the fourth quarter adding to ongoing sales generated from CBD infusion into candies and beverages that could bring the company to or over $1 million in revenue for 2019 after an accounting review.

KALY’s infusion and extraction business supplements the company’s primary cannabis biopharmaceutical technology development objectives. To date, KALY has an intellectual property portfolio that contains a deep pipeline of cannabinoid biopharmaceutical product candidates including four distinct compounds listed here: 

Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;

Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;

Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and

Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.

In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditionsKALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditionsThe market for COPD treatment is anticipated to reach $14 billion by 2025. 

In addition to KALY’s ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY’s U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration.  

To stay abreast of the latest developments and learn more about the company visit  https://www.kali-extracts.com/.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
ir@kali-extracts.com

(214) 210-0459
 

Kali (PK) (USOTC:KALY)
Historical Stock Chart


From Jul 2019 to Jul 2020

Click Here for more Kali (PK) Charts.

Kali (PK) (USOTC:KALY)
Intraday Stock Chart


Tuesday 14 July 2020

Click Here for more Kali (PK) Charts.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
TSX
BCE
BCE Inc
TSX
IVN
Ivanhoe Mi..
FX
CADUSD
Canadian D..
USOTC
XUII
Xumanii In..
FX
EURCAD
Euro vs Ca..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:ca D:20200714 11:22:32